**Basal Cell Carcinoma: Identification and Management**

|  |  |
| --- | --- |
| Resource | Address |
| Ascierto PA, et al. Immunotherapy in non-melanoma skin cancer: Updates and new perspectives. *Drugs Context*. 2019;8:212583. | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434981/](about:blank) |
| Carballo GB, et al. A highlight on sonic hedgehog pathway. *Cell Commun Signal*. 2018;16:11. | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861627/](about:blank) |
| Cameron MC, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. *J Am Acad Dermatol*. 2019;80:303-317. | [https://pubmed.ncbi.nlm.nih.gov/29782900/](about:blank) |
| Cameron MC, et al. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. *J Am Acad Dermatol*. 2019;80:321-339. | [https://pubmed.ncbi.nlm.nih.gov/29782901/](about:blank) |
| Chang ALS, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. *J Am Acad Dermatol*. 2019;80:564-566. | [https://www.jaad.org/article/S0190-9622(18)32471-X/pdf](about:blank) |
| Chen DS, et al. Oncology meets immunology: The cancer-immunity cycle. *Immunity.* 2013;39:1-10. | [https://pubmed.ncbi.nlm.nih.gov/23890059/](about:blank) |
| Danesh MJ, et al. Adherence to the National Comprehensive Cancer Network Criteria of Complete Circumferential Peripheral and Deep Margin Assessment in Treatment of High-Risk Basal and Squamous Cell Carcinoma. *Dermatologic Surg*. 2020;46:1473-1480. | [https://pubmed.ncbi.nlm.nih.gov/32149872/](about:blank) |
| Dréno B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial. *Lancet Oncol.* 2017;18:404-412. | [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30072-4/fulltext](about:blank) |
| Dummer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. *Br J Dermatol*. 2020;182:1369-1378. | [https://pubmed.ncbi.nlm.nih.gov/31545507/](about:blank) |
| McDaniel B, et al. Basal Cell Carcinoma. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. Updated November 20, 2020. | [https://www.ncbi.nlm.nih.gov/books/NBK482439/](about:blank) |
| Migden MR, et al. Emerging trends in the treatment of advanced basal cell carcinoma. *Cancer Treat Rev*. 2018;64:1-10. | [https://pubmed.ncbi.nlm.nih.gov/29407368/](about:blank) |
| Morgan FC, et al. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. *J Am Acad Dermatol*. 2020;83:832-838. | [https://pubmed.ncbi.nlm.nih.gov/31600531/](about:blank) |
| Paulson KG, et al. Immunotherapy for skin cancer. *Int Immunol*. 2019;31:465-475. | [https://pubmed.ncbi.nlm.nih.gov/30753483/](about:blank) |
| Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. *BMC Cancer*. 2017;17:332. | [https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3286-5](about:blank) |
| Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Eng J Med*. 2012;366:2171-2179. | [https://www.nejm.org/doi/full/10.1056/nejmoa1113713](about:blank) |
| Stratigos AJ, et al. LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). *Ann Oncology*. 2020;31(suppl 4):S1175-S1176. | [https://www.annalsofoncology.org/article/S0923-7534(20)42359-2/abstract](about:blank) |
| Stratigos AJ, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. *Eur J Cancer*. 2020;128:83-102. | [https://pubmed.ncbi.nlm.nih.gov/32113942/](about:blank) |
| Tanese K. Diagnosis and management of basal cell carcinoma. *Curr Treat Options Oncol* 2019;20:13. | [https://pubmed.ncbi.nlm.nih.gov/30741348/](about:blank) |
| Totonchy M, et al. Emerging concepts and recent advances in basal cell carcinoma. *F1000Res*. 2017;6:2085. | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717469/](about:blank) |
| Xie P, et al. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. *J Am Acad Dermatol.* 2018;79:1089-1100.e17. | [https://pubmed.ncbi.nlm.nih.gov/30003981/](about:blank) |

**Resources and Societies**

|  |  |
| --- | --- |
| Resource | Address |
| American Academy of Dermatology (AAD). *Skin Cancer.* | [https://www.aad.org/media/stats-skin-cancer](about:blank) |
| American Cancer Society (ACS). *Basal and Squamous Cell Skin Cancer*. | [https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html](about:blank) |
| American Society of Clinical Oncology (ASCO). | [https://www.asco.org/](about:blank) |
| Centers for Disease Control and Prevention (CDC). *What Is Skin Cancer?* | [https://www.cdc.gov/cancer/skin/basic\_info/what-is-skin-cancer.htm](about:blank) |
| National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 1.2020.* | [https://www.nccn.org/professionals/physician\_gls/pdf/nmsc.pdf](about:blank) |
| Skin Cancer Foundation. *Basal Cell Carcinoma Overview.* | [https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/](about:blank) |